About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products.
Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1.
Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor.
The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.